J Gastroenterol. 2013 Oct 1. [Epub ahead of print]
Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C.
Sugawara K, Inao M, Nakayama N, Mochida S.
Source
Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama-Machi, Iruma-Gun, Saitama, 350-0495, Japan.
Abstract
BACKGROUND:
The significance of retinopathy during triple therapy with telaprevir is uncertain.
METHODS:
Ophthalmologic examination was done prospectively before and every month during the therapy in 95 CHC patients.
RESULTS:
Retinopathy was found in 46 (48.4 %), and the specialists recommended discontinuation of the therapy in 9 (9.5 %). Such lesions may develop as adverse effects by telaprevir, since the lesions disappeared following discontinuation of telaprevir in a 65-year-old man, in whom both pegylated-interferon (Peg-IFN) and ribavirin were continued, and reappeared when he took telaprevir again by his decision. Multivariate analysis revealed that interleukin 28B single-nucleotide polymorphism (IL28B SNP) and anemia development during the therapy were independent factors associating retinopathy.
CONCLUSION:
Ophthalmologic examinations should be done carefully during triple therapy, since the incidence was higher than that in previous Peg-IFN therapy, and lesions may develop as adverse effects by telaprevir, but not by Peg-IFN, especially in those showing preferable IL28B SNPs allele and/or anemia during the therapy.
Related On The Website
Aug 28 2013
Could interferon-based therapies for chronic
hepatitis C cause retinopathy?
Interferon-Associated
Retinopathy During HCV Therapy
To assess the incidence of retinopathy in
patients with chronic hepatitis C being treated with interferon-based regimens
and estimate the rate of resolution. A systematic literature search was
performed to locate all relevant publications. Pooled
incidence of
retinopathy was calculated in patients treated with interferon or pegylated
interferon. We also estimated the rate of discontinuation of treatment and
resolution after the treatment was stopped
All kinds of issues seem to be developing with Telaprevir (these lesions, plus earlier reported skin reactions, etc.). Boceprevir doesn't seem to link to these issues. It is interesting to see this, considering that Telaprevir seems to have gotten a bigger media-pharmacy push than Boceprevir.
ReplyDelete